Replies to post #159837 on Biotech Values

[jq1234]

PTLA: More interesting IPO than many other recent IPOs to me. I am skeptical of Betrixaban too, everyone should with its history. Even if I weren't, it would still be too little too late. PRT4445, on the other hand, could be a real important product. There isn't much clinical data yet, worth watching closely. Syk and JAK are pretty much validated targets to me, thus depends on specific drug. They have a lot of cash too, profitable for the past two years, very rare. I haven't read their filing yet. It would be interesting to see how the market value the company.

[DewDiligence]

Portola (PTLA)—Looks like Dew is fairly skeptical on…betrixaban and the related product in Phase 2 (PRT4445).

I’m not skeptical of PRT4445 per se, but rather of ability of PRT4445 to salvage Betrixaban. From #msg-82410316 (Dec 2012):

…I don’t think PRT4445 will be able to salvage Portola’s Betrixaban program, but it may end up helping Eliquis.

The same may now be said about Xarelto.